Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.40 |
| ▸ | ABL1 | P00519 | 2/20 | 0.40 |
| ▸ | EGFR | P00533 | 2/20 | 0.40 |
| ▸ | HCK | P08631 | 2/20 | 0.40 |
| ▸ | SRC | P12931 | 2/20 | 0.40 |
| ▸ | KDR | P35968 | 2/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.40 |
| ▸ | MTOR | P42345 | 2/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.40 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.40 |
| ▸ | PRKDC | P78527 | 2/20 | 0.40 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.40 |
| ▸ | CFTR | P13569 | 2/20 | 0.36 |
| ▸ | BUB1 | O43683 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 6/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3835028 | 0.81 | MAPT (0.43) | HTR6PIK3CDABL1EGFRHCK | |
| SCHEMBL10117911 | 0.79 | PIK3CD (0.43) | HTR6PIK3CDABL1EGFRHCK | |
| SCHEMBL5481092 | 0.78 | MAP4K1 (0.35) | HTR6PIK3CDCFTRNR1H2DGAT1 | |
| SCHEMBL3033379 | 0.77 | HTR6 (0.48) | HTR6PIK3CDABL1EGFRHCK | |
| SCHEMBL1053699 | 0.76 | KMT2A (0.41) | HTR6PIK3CDABL1EGFRHCK | |
| SCHEMBL3046607 | 0.76 | HTR6 (0.44) | HTR6PIK3CDABL1EGFRHCK | |
| SCHEMBL30230816 | 0.75 | TUBB1 (0.55) | HTR6PIK3CDABL1EGFRHCK | |
| SCHEMBL2266733 | 0.75 | TUBB1 (0.55) | HTR6PIK3CDABL1EGFRHCK | |
| SCHEMBL1273077 | 0.74 | HTR6 (0.49) | HTR6PIK3CDABL1EGFRHCK | |
| SCHEMBL3269495 | 0.74 | PIK3CD (0.47) | HTR6PIK3CDABL1EGFRHCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070105851-A1 | Indolyl-thienopyrazinone derivatives useful for treating hyperproliferative disorders and diseases associated with angiogenesis | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-05-10 | — | — | US | disclosed |
| US-20070105851-A1 | Indolyl-thienopyrazinone derivatives useful for treating hyperproliferative disorders and diseases associated with angiogenesis | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-05-10 | — | — | US | disclosed |
| US-20070105851-A1 | Indolyl-thienopyrazinone derivatives useful for treating hyperproliferative disorders and diseases associated with angiogenesis | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-05-10 | — | — | US | disclosed |
| US-20060004011-A1 | Indolyl pyrazinone derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-01-05 | — | — | US | disclosed |
| EP-1565455-A1 | INDOLYL PYRAZINONE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | Bayer Pharmaceuticals Corporation (US) | 2005-08-24 | — | — | EP | disclosed |
| WO-2004043950-A1 | INDOLYL PYRAZINONE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105851-A1 | Indolyl-thienopyrazinone derivatives useful for treating hyperproliferative disorders and diseases associated with angiogenesis | MKI67, CDK4, PGF | HTR6 752/4885PIK3CD 426/4885ABL1 173/4885 |
| US-20060004011-A1 | Indolyl pyrazinone derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | MKI67, VEGFA, FLT1 | HTR6 1273/4885PIK3CD 624/4885ABL1 868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.